cbdMD Supports Proposed Hemp Guardrails Act Ahead of December 11 Regulatory Change
cbdMD says the proposed Hemp Guardrails Act could establish federal requirements for hemp-derived products and prevent a December 11, 2026 redefinition from removing a broad range of lawful products from the market.
cbdMD, Inc. (NYSE American:YCBD) has announced its support for the proposed Hemp Guardrails Act, bipartisan legislation introduced by Senators Tim Sheehy (R-MT) and Amy Klobuchar (D-MN) on November 17. The company says the bill would create federal standards for hemp-derived products before a redefinition scheduled to take effect on December 11, 2026.
The legislation would set requirements for the sale and manufacture of hemp-derived cannabinoid products. Sales would be limited to adults 21 and older, while packaging would need to be child-resistant and include QR codes connecting consumers with third-party certificates of analysis.
The proposal would also direct the FDA to establish rules covering manufacturing, product testing, facility registration and recalls. Hemp would be required to be grown, processed and packaged in the United States.
Under the proposed framework, hemp products could not contain more than trace amounts of intoxicating cannabinoids other than delta-9 THC and a few other compounds. The bill would also retain the restriction on synthetic cannabinoids that do not occur naturally in the hemp plant.
cbdMD Chief Executive Officer Ronan Kennedy said the company supports regulation focused on consumer protections while retaining lawful agricultural, manufacturing and retail activity. The company said the hemp sector supports an estimated 350,000 American jobs across farmers, manufacturers, distributors and retailers, and contributes tax revenue to states and local communities.
cbdMD says the redefinition due to take effect on December 11 would remove a broad range of lawful hemp-derived products from the market if Congress does not act. Kennedy has urged Congress to include the proposed legislation in the year-end funding package before that date.
The Hemp Guardrails Act remains proposed legislation. The source material identifies the bill's passage in its current form as a risk affecting the company's forward-looking statements.
cbdMD said its acquisition of the Twinlab, Metabolife and Reserveage brands expanded its nutritional supplement business beyond products dependent on hemp-derived cannabinoids. The company's stated brand portfolio also includes ResVitale, cbdMD, Paw CBD, Oasis and Bluebird Botanicals.
The company describes its products as being sold through retail, wholesale and direct-to-consumer channels. It is headquartered in Charlotte, North Carolina, and said it has invested in product safety through third-party testing and published research on its ingredients.
cbdMD said it is prepared to work with lawmakers and the FDA on implementation of the proposed framework. The company also said the broader supplement portfolio would provide a federal pathway for hemp-derived dietary supplements if the legislation passes, although the bill's outcome and final form remain unsettled.
cbdMD, Inc. announced its support for the Hemp Guardrails Act, bipartisan legislation introduced by Senators Tim Sheehy and Amy Klobuchar. The proposed bill would establish a federal regulatory framework for hemp-derived products and avert the implementation of a redefinition that cbdMD says would effectively ban many lawful products nationwide.
The Hemp Guardrails Act was introduced on November 17, while the redefinition it is intended to address is scheduled to take effect on December 11, 2026. cbdMD says that redefinition would remove a broad range of lawful hemp-derived products from the market.
The proposed legislation would restrict hemp-derived cannabinoid products to adults aged 21 and older, require child-resistant packaging and QR codes linking to third-party certificates of analysis, and direct the FDA to set manufacturing, testing, facility registration and recall standards. It would also require hemp to be grown, processed and packaged in the United States.
The bill would prohibit hemp products from containing more than trace amounts of intoxicating cannabinoids other than delta-9 THC and a few other compounds. It would also maintain the prohibition on synthetic cannabinoids that do not occur naturally in the hemp plant.
cbdMD says the bill would protect consumers through age-21 sales, child-resistant packaging, third-party testing, FDA manufacturing standards and clear labelling while preserving farms, manufacturers and retailers supporting an estimated 350,000 American jobs. Chief Executive Officer Ronan Kennedy said responsible operators had asked for clear rules and that a ban could push consumers towards unregulated products and cost Americans their jobs.
cbdMD says the hemp redefinition taking effect on December 11 would remove a broad range of lawful products from the market. The company also says the hemp sector supports approximately 350,000 jobs across American farmers, manufacturers, distributors and retailers and generates substantial tax revenue for states and local communities.
Ronan Kennedy urged Congress to include the Hemp Guardrails Act in the year-end funding package before December 11. The company said it stands ready to work with lawmakers and the FDA on implementation.
cbdMD says its recent acquisition of the Twinlab, Metabolife and Reserveage brands added an established portfolio of nutritional supplements that does not rely on hemp-derived cannabinoids. The company describes its broader platform as spanning those brands alongside ResVitale, cbdMD, Paw CBD, Oasis and Bluebird Botanicals.
cbdMD says its diversified wellness platform helps de-risk the business against federal and state regulatory change, whatever the outcome in Congress. Kennedy said Twinlab provides scale and diversification across the broader supplement market, while the company says passage of the proposed legislation could provide a federal pathway for hemp-derived dietary supplements.
cbdMD, Inc. is a wellness company headquartered in Charlotte, North Carolina, with brands spanning nutritional supplements and hemp-derived wellness products. Its products are offered through retail, wholesale and direct-to-consumer channels.
cbdMD says it has invested in product safety through third-party testing of its products and published research on its ingredients. The company also said it is prepared to work with lawmakers and the FDA on implementation of the proposed framework.
cbdMD, Inc. is listed on the NYSE American under the ticker symbol YCBD.